ESR1 and breast carcinoma: Since a similar pro-tumorigenic role of AR has also been observed in ERα-/HER2-positive (HER2+) breast cancers [37], AR blockage has been proposed as an effective treatment strategy in ERα- breast cancer [38,39,40].